サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1352919

慢性閉塞性肺疾患（COPD）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年から2030年までの予測

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 168 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
慢性閉塞性肺疾患（COPD）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年から2030年までの予測
出版日: 2023年09月01日
発行: Value Market Research
ページ情報: 英文 168 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性閉塞性肺疾患（COPD）治療市場の世界需要は、調査期間2023～2030年のCAGR 6.62%で、2022年の230億2,000万米ドルから2030年にはほぼ384億4,000万米ドルの市場規模に達すると推定されます。

肺の炎症は慢性閉塞性肺疾患（COPD）の原因となり、肺からの気流を遮断します。COPDは、喘鳴、粘液分泌、呼吸困難などの症状を伴う慢性疾患です。この肺疾患は、難治性の喘息、肺気腫、慢性気管支炎からなります。COPDは、喫煙、大気汚染、副流煙、α1欠乏症関連肺気腫（まれなCOPDの一種）などが原因で発症することがほとんどです。合併症を避けられる場合もあれば、病気の進行を抑えられる場合もあります。禁煙、処方された薬を指示通りに服用すること、インフルエンザや肺炎などの感染症に対する予防接種を受け、合併症を予防することなどが挙げられます。

市場力学：

3剤併用療法やデジタル吸入器の人気が高まっていることから、慢性閉塞性肺疾患（COPD）治療市場の参入企業は調査期間中に需要が増加すると予測されます。慢性閉塞性肺疾患を発症する危険因子の増加により、慢性閉塞性肺疾患は一般的な疾患となり、政府やヘルスケア機関はより良い治療を提供する必要に迫られています。さらに、COPDの予防に対する一般市民の意識も高まっており、これがこの市場を押し上げると予測されています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは慢性閉塞性肺疾患（COPD）治療の世界市場における各セグメントを包括的に評価することもできます。慢性閉塞性肺疾患（COPD）治療産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける慢性閉塞性肺疾患（COPD）治療市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 慢性閉塞性肺疾患（COPD）治療- 産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：薬剤クラス別

  • 薬剤クラス別概要
  • 実績データと予測データ
  • 薬剤クラス別分析
  • 併用療法
  • 気管支拡張薬
  • コルチコステロイド
  • ホスホジエステラーゼ4型阻害薬
  • ムコキネティクス
  • その他

第7章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：タイプ別

  • タイプ別概要
  • 実績データと予測データ
  • タイプ別分析
  • 慢性気管支炎
  • 肺気腫

第8章 慢性閉塞性肺疾患（COPD）治療薬世界市場売上高分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 慢性閉塞性肺疾患（COPD）治療の世界市場売上高分析：地域別

  • 地域別展望販売分析
  • イントロダクション売上分析
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東とアフリカ

第10章 慢性閉塞性肺疾患（COPD）治療薬企業の競合情勢

  • 慢性閉塞性肺疾患（COPD）治療市場競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第11章 企業プロファイル

  • 上位10社のシェア分析
  • 市場集中度
  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion PharmaceuticalsInc.（Sumitomo Dainippon Pharma Co. Ltd.）
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Obstructive Pulmonary Disease (Copd) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218849

The global demand for Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is presumed to reach the market size of nearly USD 38.44 BN by 2030 from USD 23.02 BN in 2022 with a CAGR of 6.62% under the study period 2023 - 2030.

Inflammation of the lungs contributes to chronic obstructive pulmonary disease (COPD), which blocks airflow from the lungs. It is a chronic ailment with symptoms that include wheezing, mucous production, and trouble breathing. The lung condition comprises refractory asthma, emphysema, and chronic bronchitis. COPD is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors. Complications can be avoided in some situations, and illness progression can be reduced in others. These may include giving up smoking, taking prescribed medications as directed, and being vaccinated against infections like the flu, pneumonia, and others to prevent associated co-morbidities.

MARKET DYNAMICS:

Due to the growing popularity of triple therapy treatment options and digital inhaler options, market players within the chronic obstructive pulmonary disease (COPD) treatment market is projected to experience an increase in demand during the study period. Increasing risk factors for developing chronic obstructive pulmonary disease have made the condition rather common, thus forcing government and healthcare institutions to provide better treatment. Additionally, there has been an increase in public awareness of COPD prevention, which is anticipated to boost this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic obstructive pulmonary disease (copd) treatment. The growth and trends of chronic obstructive pulmonary disease (copd) treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the chronic obstructive pulmonary disease (copd) treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Chronic Obstructive Pulmonary Disease (COPD) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the chronic obstructive pulmonary disease (copd) treatment market include Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, Verona Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Combination Therapy Historic and Forecast Sales by Regions
  • 6.5 Bronchodilators Historic and Forecast Sales by Regions
  • 6.6 Corticosteroids Historic and Forecast Sales by Regions
  • 6.7 Phosphodiesterase Type 4 Inhibitor Historic and Forecast Sales by Regions
  • 6.8 Mucokinetics Historic and Forecast Sales by Regions
  • 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY TYPE

  • 7.1 Overview by Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Type
  • 7.4 Chronic Bronchitis Historic and Forecast Sales by Regions
  • 7.5 Emphysema Historic and Forecast Sales by Regions

8 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1 Overview by Distribution Channel
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Distribution Channel
  • 8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 8.6 Online Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT COMPANIES

  • 10.1. Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Almirall
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Boehringer Ingelheim International GmbH
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. CHIESI Farmaceutici S.p.A.
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. GlaxoSmithKline plc
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Kyowa Hakko Kirin
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Mylan N.V.
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Novartis AG
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Orion Corporation
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Sanofi
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Teva Pharmaceutical Industries Ltd.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Theravance Biopharma
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Verona Pharmaceuticals
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies